Département d'Anesthésie Réanimation, Centre Hospitalier Universitaire Bichat-Claude Bernard, Assistance Publique Hôpitaux de Paris, Université Paris VII, 46 Rue Henri Huchard, 75018 Paris, France.
Curr Infect Dis Rep. 2009 Jan;11(1):14-20. doi: 10.1007/s11908-009-0003-9.
Intensive care unit (ICU) patients present several unusual pharmacokinetic (PK) characteristics compared with less seriously ill patients, including increased distribution volume and variable clearance. Interpatient PK variability is often considerable and can produce a wide range of values for PK parameters and major differences in drug exposure. These analyses have led to the development of simulation techniques and population PK models to assess dosing regimens in specific patient subsets. Plasma concentrations may frequently overestimate target-site concentrations and therefore clinical efficacy. The unbound drug concentration at the infection site should be preferred. Although renal replacement therapy techniques are commonly used in ICU patients, data concerning antibiotic dosing in this setting remain limited. Administration of antibacterial agents by continuous infusion is becoming a common technique to avoid undesirable high peak concentrations and low trough concentrations and to optimize PK-pharmacodynamic indices.
与病情较轻的患者相比,重症监护病房(ICU)患者具有许多不同的药代动力学(PK)特征,包括分布容积增加和清除率可变。患者间 PK 变异性通常相当大,可导致 PK 参数值的广泛范围和药物暴露的主要差异。这些分析导致了模拟技术和群体 PK 模型的发展,以评估特定患者亚组的给药方案。血浆浓度可能经常高估靶部位浓度,从而影响临床疗效。应首选感染部位的游离药物浓度。尽管 ICU 患者常使用肾脏替代疗法技术,但有关该环境下抗生素剂量的数据仍然有限。通过连续输注给予抗菌药物正成为一种常用技术,以避免不理想的高峰浓度和低谷浓度,并优化 PK-药效学指标。